| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Bayer |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Astellas Scientific and Medical Affairs Inc |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Janssen |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: Exelixis |
| Recipient: You |
| Company: Myovant Sciences |
| Recipient: You |
| Company: Precede Bio |
| Recipient: You |
| Company: Sumitomo Pharma Oncology |
| Recipient: You |
| Company: Boundless Bio |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Bayer |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Novartis |
| Recipient: Your Institution |
| Company: Janssen Oncology |
| Recipient: Your Institution |
| Company: Astellas Pharma |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Syntrix Biosystems |
| Recipient: Your Institution |
| Company: pathos |
| Recipient: Your Institution |
| Company: FibroGen |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Circulating tumor cell novel capture technology |
| Recipient: Your Institution |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Astellas Scientific and Medical Affairs Inc |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|